Table 3.
Expression levels of miR-21, miR-146a and IL-13 according to asthma severity relying on disease characteristics among cases.
| Mild persistent cases n = 16 (59.3%) | Moderate persistent cases n = 11 (40.7%) | Test of significance and P-value | |
|---|---|---|---|
| miR-21 relative expression up-regulationa | 53.55-fold | 55.31-fold | t-test = 0.7, P = 0.47 |
| miR-146a relative expression up-regulationa | 2.3-fold | 3.53-fold | t-test = 0.03, P = 0.9 |
| IL-13 (pg/ml), mean ± SD | 22 ± 7.1 | 18 ± 3.3 | t-test = 1.4, P = 0.2 |
| FEV1 %, mean ± SD | 89.2 ± 7.7 | 73.7 ± 4.5 | t-test = 6, P < 0.05 |
FEV1: forced expiratory volume in the first second.
a
Mean of relative expression (fold-changes) was calculated according to replicate of 2−ΔΔCT values for miR-21 and miR-146a in each of the mild and moderate groups.